• Mutation; HGNC; 882; ATR; Unexplicit; Ex29-34del; Zygosity=Heterozygous (PubMed=16827800).
  

PubMed=8152260
Gong J.-H., Maki G., Klingemann H.-G.
Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells.
Leukemia 8:652-658(1994)

PubMed=9118301
Klingemann H.-G., Wong E., Maki G.
A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood.
Biol. Blood Marrow Transplant. 2:68-75(1996)

PubMed=9573023; DOI=10.1182/blood.V91.10.3850
Nagashima S., Mailliard R., Kashii Y., Reichert T.E., Herberman R.B., Robbins P., Whiteside T.L.
Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo.
Blood 91:3850-3861(1998)

PubMed=10365666; DOI=10.1089/10430349950018030
Tam Y.K., Maki G., Miyagawa B., Hennemann B., Tonn T., Klingemann H.-G.
Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy.
Hum. Gene Ther. 10:1359-1373(1999)

PubMed=10803505; DOI=10.1038/sj.leu.2401778
Drexler H.G., Matsuo Y.
Malignant hematopoietic cell lines: in vitro models for the study of natural killer cell leukemia-lymphoma.
Leukemia 14:777-782(2000)

DOI=10.1016/B978-0-12-221970-2.50457-5
Drexler H.G.
The leukemia-lymphoma cell line factsbook.
(In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001)

PubMed=11454312; DOI=10.1089/152581601750288975
Maki G., Klingemann H.-G., Martinson J.A., Tam Y.K.
Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92.
J. Hematother. Stem Cell Res. 10:369-383(2001)

PubMed=12850795; DOI=10.1080/14653240310001523
Tam Y.K., Martinson J.A., Doligosa K., Klingemann H.-G.
Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy.
Cytotherapy 5:259-272(2003)

PubMed=16827800; DOI=10.1111/j.1349-7006.2006.00226.x
Liu A., Takakuwa T., Luo W.-J., Fujita S., Aozasa K.
Alterations in ATR in nasal NK/T-cell lymphoma and chronic active Epstein-Barr virus infection.
Cancer Sci. 97:605-610(2006)

PubMed=18424763; DOI=10.4049/jimmunol.180.9.6392
Binyamin L., Alpaugh R.K., Hughes T.L., Lutz C.T., Campbell K.S., Weiner L.M.
Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy.
J. Immunol. 180:6392-6401(2008)

PubMed=19194464; DOI=10.1038/leu.2009.3
Iqbal J., Kucuk C., Deleeuw R.J., Srivastava G., Tam W., Geng H., Klinkebiel D., Christman J.K., Patel K., Cao K., Shen L., Dybkaer K., Tsui I.F.L., Ali H., Shimizu N., Au W.Y., Lam W.L., Chan W.C.
Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies.
Leukemia 23:1139-1151(2009)

PubMed=20454443; DOI=10.1155/2010/904767
Uphoff C.C., Denkmann S.A., Steube K.G., Drexler H.G.
Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human and other primate cell lines.
J. Biomed. Biotechnol. 2010:904767.1-904767.23(2010)

PubMed=21052088; DOI=10.1038/leu.2010.255
Iqbal J., Weisenburger D.D., Chowdhury A., Tsai M.Y., Srivastava G., Greiner T.C., Kucuk C., Deffenbacher K., Vose J.M., Smith L., Au W.Y., Nakamura S., Seto M., Delabie J., Berger F., Loong F., Ko Y.-H., Sng I., Liu X., Loughran T.P. Jr., Armitage J.O., Chan W.C.
Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic gammadelta T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro.
Leukemia 25:348-358(2011)

PubMed=21570725; DOI=10.1016/j.molimm.2011.04.010
Schnueriger A., Grau R., Sondermann P., Schreitmueller T., Marti S., Zocher M.
Development of a quantitative, cell-line based assay to measure ADCC activity mediated by therapeutic antibodies.
Mol. Immunol. 48:1512-1517(2011)

PubMed=25586472; DOI=10.1038/ncomms7025
Kucuk C., Jiang B., Hu X.-Z., Zhang W.-Y., Chan J.K.C., Xiao W.-M., Lack N., Alkan C., Williams J.C., Avery K.N., Kavak P., Scuto A., Sen E., Gaulard P., Staudt L.M., Iqbal J., Zhang W.-W., Cornish A., Gong Q., Yang Q.-P., Sun H., d'Amore F.A., Leppa S., Liu W.-P., Fu K., de Leval L., McKeithan T., Chan W.C.
Activating mutations of STAT5B and STAT3 in lymphomas derived from gammadelta-T or NK cells.
Nat. Commun. 6:6025.1-6025.12(2015)

PubMed=26559813; DOI=10.1007/s00262-015-1761-x
Suck G., Odendahl M., Nowakowska P., Seidl C., Wels W.S., Klingemann H.-G., Tonn T.
NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy.
Cancer Immunol. Immunother. 65:485-492(2016)

PubMed=30054012; DOI=10.1016/j.molimm.2018.07.015
Gunesch J.T., Angelo L.S., Mahapatra S., Deering R.P., Kowalko J.E., Sleiman P., Tobias J.W., Monaco-Shawver L., Orange J.S., Mace E.M.
Genome-wide analyses and functional profiling of human NK cell lines.
Mol. Immunol. 115:64-75(2019)

PubMed=31126350; DOI=10.1186/s40425-019-0612-2
Yang H.G., Kang M.C., Kim T.Y., Hwang I., Jin H.T., Sung Y.C., Eom K.-S., Kim S.W.
Discovery of a novel natural killer cell line with distinct immunostimulatory and proliferative potential as an alternative platform for cancer immunotherapy.
J. Immunother. Cancer 7:138.1-138.17(2019)

PubMed=31160637; DOI=10.1038/s41598-019-44491-x
Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M., MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.
The LL-100 panel: 100 cell lines for blood cancer studies.
Sci. Rep. 9:8218-8218(2019)

PubMed=34349345; DOI=10.1007/s10616-021-00476-1
Zhao H., Zhou Z.-L., Li G.-M., Liu G., Lin S.-Y., Chen W., Xiong S.
An NK cell line (NK92-41BB) expressing high levels of granzyme is engineered to express the high affinity chimeric genes CD16/CAR.
Cytotechnology 73:539-553(2021)